Tuberculosis Screening Protocol Before Tofacitinib Therapy
All patients must undergo tuberculosis screening with either tuberculin skin test (TST) or interferon-gamma release assay (IGRA) plus chest radiograph before initiating tofacitinib, with IGRA preferred in BCG-vaccinated patients. 1, 2
Initial Screening Requirements
Step 1: Perform TST or IGRA
- Use IGRA preferentially if patient has history of BCG vaccination 1
- Do NOT perform anergy panel testing 1
- If patient is already immunosuppressed and false-negative results are more likely, consider repeating the screening test 1
Step 2: Obtain Chest Radiograph
- Required for all patients regardless of TST/IGRA result 1, 3
- Consider chest radiography even with negative TST/IGRA if patient has TB risk factors 1
Interpretation and Management Algorithm
If TST/IGRA is Negative:
- Presume uninfected
- May start tofacitinib immediately 1
If TST/IGRA is Positive with Negative Chest X-ray:
- Diagnosis: Latent TB
- Complete at least 1 month of latent TB treatment before starting tofacitinib 1, 3
- Standard regimens: isoniazid for 6 months total, rifampicin plus isoniazid for 3 months total, or rifampicin alone for at least 4 months total 3
- After completing 1 month of treatment, may start tofacitinib while continuing TB prophylaxis 1
Critical Caveat: Rifampin significantly reduces tofacitinib efficacy through drug interactions. Discontinuation rates within 6 months are substantially higher (38.9% vs 11.2%) when tofacitinib is co-administered with rifampin 4. Consider rifampin-free regimens or completing full TB prophylaxis course before starting tofacitinib when clinically feasible.
If Chest X-ray Shows Active TB:
- Obtain sputum for acid-fast bacilli smear and culture 1
- Diagnosis: Active TB
- Complete full treatment course for active TB before initiating tofacitinib 1
- Consider referral to TB specialist 1
TB Risk Factors Requiring Annual Rescreening
Rescreen annually if patient has ongoing TB exposure risk factors: 1
- Close contacts of persons with known/suspected active TB
- Foreign-born from high-incidence areas (Africa, Asia, Eastern Europe, Latin America, Russia)
- Frequent/prolonged visits to high-prevalence TB areas
- Residents/employees of congregate settings (correctional facilities, long-term care, homeless shelters)
- Healthcare workers serving high-risk populations
- Medically underserved/low-income populations
- Persons who abuse drugs or alcohol
- Infants/children/adolescents exposed to high-risk adults
Special Considerations
Drug Interactions: The recommended tofacitinib dose when taking potent CYP3A4 inhibitors (e.g., ketoconazole) or combined moderate CYP3A4 and potent CYP2C19 inhibitors (e.g., fluconazole) is 5 mg once daily 5
Monitoring During Treatment: Maintain high index of suspicion for TB during treatment and for 6 months after discontinuation, especially in high-risk patients 3. Patients previously positive for TST/IGRA will often remain positive even after successful TB treatment, so monitor for clinical signs/symptoms rather than repeat testing 1
Real-World Context: Despite guidelines, adherence to TB screening before biologic/JAK inhibitor therapy remains suboptimal in practice (only 40-48% in some populations) 6. The risk of TB with tofacitinib appears similar to TNF inhibitors 7, 8, with dose-dependent risk (higher with 10 mg twice daily versus 5 mg twice daily) 9.